Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Table 1 Characteristics of studies included for the meta-analysis

Trial	Design	Design details	Enrollment size (no.)	Drug	Dose (mg/kg)	CTC for AE version
Antonia (2017) [4]	RCT	double-blind, multicenter, phase III	475	Durvalumab	10, q2w	4
Borghaei (2015) [5]	RCT	open-label, multicenter, phase III	287	Nivolumab	3, q2w	4
Brahmer (2015) [6]	RCT	open-label, multicenter, phase III	131	Nivolumab	3, q2w	4
Carbone (2017) [7]	RCT	open-label, multicenter, phase III	267	Nivolumab	3, q2w	4
Fehrenbacher (2016) [8]	RCT	open-label, multicenter, phase II	142	Atezolizumab	1200 mg, q3w	4
Garassino (2018) [9]	Single-arm	open-label, multicenter, phase II	444	Durvalumab	10, q2w	4
Garon (2015) [10]	Single-arm	open-label, multicenter, phase Ib	495	Pembrolizumab	2, q3w; 10, q3w; 10, q2w	4
Gettinger (2016) [11]	Single-arm	open-label, multicohort, phase I	52	Nivolumab	3, q2w	4
Gettinger (2015) [12]	RT	dose-escalation cohort expansion, phase I	129	Nivolumab	1,3,10,q2w	3
Herbst (2016) [13]	RCT	open-label, multicenter, phase II/III	682	Pembrolizumab	2, 10, q3w	4
Peters (2017) [14]	Single-arm	open-label, multicenter, phase II	659	Atezolizumab	1200 mg, q3w	4
Reck (2016) [15]	RCT	open-label, multicenter, phase III	154	Pembrolizumab	200 mg q3w	4
Rittmeyer (2017) [16]	RCT	open-label, multicenter, phase III	609	Atezolizumab	1200 mg q3w	4
Rizvi (2015) [17]	Single-arm	open-label, multicenter, phase II	117	Nivolumab	3, q2w	4
Gulley (2017) [18]	Single-arm	open-label, multicenter, phase II	184	Avelumab	10, q2w	4
Waterhouse (2018) [24]	Single-arm	open-label, community-based, phase IIIb/IV	1420	Nivolumab	3, q2w	4

CTC for version, Common Terminology Criteria for Adverse Events version; RCT, Research clinical trial; n/a, not available